 |
|
|
| |
Pharmacokinetics and Safety of Hepatitis C Virus
Nonstructural Protein 5A Inhibitor MK-8742 in
Cirrhotic Patients With Mild and Moderate Hepatic Insufficiency
|
| |
| |
Reported by Jules Levin
15th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy, Washington DC; May 19-21, 2014
WL Marshall1, G Garrett1, WW Yeh1, L Caro1, H-P Feng1, X Huang1, KC Lasseter2, RA Preston3, T Marbury4 and JR Butterton1
1Merck & Co. Inc, Whitehouse Station NJ, USA, 2Clinical Pharmacology of Miami, Miami, FL, USA, 3Division of Clinical Pharmacology, Miller School of Medicine, University of Miami, FL USA, and 4Orlando Clinical Research Center, Orlando, FL, USA
|
| |
|
|
|
|
|
